Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion
View Patent ↗This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4 + cell, but not a T cell-tropic isolate of HIV-1 to a CD4 + cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4 + cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4 + cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies. This invention further provides: methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1 which comprises contacting the CD4 + cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion; and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4 + cell susceptible to infection by a T cell-tropic isolate of HIV-1 which comprises contacting the CD4 + cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion.
1. An anti-PM1 monoclonal antibody which (A) significantly inhibits macrophage-tropic HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env JRFL with a CD4+ PM1 cell, and (B) does not significantly inhibit T cell-tropic HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env LAI with a HeLa-CD4+ cell.
2. A method of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD4+ primary macrophage, which comprises contacting the CD4+ primary macrophage with the monoclonal antibody of claim 1 in an amount effective to inhibit such fusion.
3. A composition comprising the monoclonal antibody of claim 1 in an amount effective to inhibit fusion of a macrophage-tropic primary isolate of HIV-1 with a CD4+ primary macrophage, and a pharmaceutically acceptable carrier.